FCCC LOGO Faculty Publications
Hoppe RT , Advani RH , Ai WZ , Ambinder RF , Aoun P , Bello CM , Benitez CM , Bierman PJ , Blum KA , Chen R , Dabaja B , Forero A , Gordon LI , Hernandez-Ilizaliturri FJ , Hochberg EP , Huang J , Johnston PB , Khan N , Maloney DG , Mauch PM , Metzger M , Moore JO , Morgan D , Moskowitz CH , Mulroney C , Poppe M , Rabinovitch R , Seropian S , Tsien C , Winter JN , Yahalom J , Burns JL , Sundar H , National comprehensive cancer network
Hodgkin lymphoma, version 2.2015
J Natl Compr Canc Netw. 2015 May;13(5) :554-86
PMID: 25964641    PMCID: PMC4898052    URL: https://www.ncbi.nlm.nih.gov/pubmed/25964641
Back to previous list
Abstract
Hodgkin lymphoma (HL) is an uncommon malignancy involving lymph nodes and the lymphatic system. Classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma are the 2 main types of HL. CHL accounts for most HL diagnosed in the Western countries. Chemotherapy or combined modality therapy, followed by restaging with PET/CT to assess treatment response using the Deauville criteria (5-point scale), is the standard initial treatment for patients with newly diagnosed CHL. Brentuximab vedotin, a CD30-directed antibody-drug conjugate, has produced encouraging results in the treatment of relapsed or refractory disease. The potential long-term effects of treatment remain an important consideration, and long-term follow-up is essential after completion of treatment.
Notes
Hoppe, Richard T Advani, Ranjana H Ai, Weiyun Z Ambinder, Richard F Aoun, Patricia Bello, Celeste M Benitez, Cecil M Bierman, Philip J Blum, Kristie A Chen, Robert Dabaja, Bouthaina Forero, Andres Gordon, Leo I Hernandez-Ilizaliturri, Francisco J Hochberg, Ephraim P Huang, Jiayi Johnston, Patrick B Khan, Nadia Maloney, David G Mauch, Peter M Metzger, Monika Moore, Joseph O Morgan, David Moskowitz, Craig H Mulroney, Carolyn Poppe, Matthew Rabinovitch, Rachel Seropian, Stuart Tsien, Christina Winter, Jane N Yahalom, Joachim Burns, Jennifer L Sundar, Hema eng P30 CA006973/CA/NCI NIH HHS/ T32 GM007790/GM/NIGMS NIH HHS/ Practice Guideline J Natl Compr Canc Netw. 2015 May;13(5):554-86. doi: 10.6004/jnccn.2015.0075.